Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses

	AASLD 2023 nov 10-14 https://www.aasld.org/the-liver-meeting